Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes

BACKGROUND: Oral semaglutide is the first oral formulation of a glucagon-like peptide 1 (GLP-1) receptor agonist to be approved in the United States for glycemic control in people with type 2 diabetes mellitus (T2DM). While oral semaglutide is not indicated for reduction of cardiovascular event risk...

Full description

Bibliographic Details
Main Authors: Chapman, R.H (Author), Fazioli, K. (Author), Guzauskas, G.F (Author), Hansen, R.N (Author), Pearson, S.D (Author), Rind, D.M (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
add on therapy
adolescent
Adolescent
adult
Adult
aged
Aged
Aged, 80 and over
antidiabetic agent
Article
body weight disorder
cardiovascular mortality
cardiovascular risk
combination drug therapy
cost benefit analysis
cost effectiveness analysis
cost utility analysis
Cost-Benefit Analysis
Diabetes Mellitus, Type 2
diabetic complication
diabetic microangiopathy
drug cost
drug efficacy
Drug Therapy, Combination
economic model
economics
empagliflozin
female
Female
glucagon like peptide
Glucagon-Like Peptides
health care cost
health status
heart failure
human
Humans
hypoglycemia
Hypoglycemic Agents
insulin
kidney disease
liraglutide
male
Male
Markov decision process
metformin
middle aged
Middle Aged
Models, Economic
network meta-analysis
non insulin dependent diabetes mellitus
outcome assessment
prospective study
quality adjusted life year
Quality-Adjusted Life Years
semaglutide
simulation
sitagliptin
sulfonylurea
treatment withdrawal
United States
very elderly
young adult
Young Adult
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items